MRK
Merck & Company Inc
NYSE: MRK · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$109.18
-1.60% today
Updated 2026-04-29
Market cap
$274.03B
P/E ratio
15.24
P/S ratio
4.22x
EPS (TTM)
$7.28
Dividend yield
2.94%
52W range
$71 – $124
Volume
9.8M
Merck & Company Inc (MRK) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
8 of 8
Last 8 quarters
Avg EPS surprise
+4.7%
Last 4 quarters
Revenue YoY growth
+5.0%
Most recent quarter
EPS YoY growth
+18.6%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+0.3%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
+4.4%
2026-02-03
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-03 | $2.04 | +1.5% | $113.37 | $118.33 | +4.4% |
| 2025-10-30 | $2.58 | +8.9% | $85.85 | $85.26 | -0.7% |
| 2025-07-29 | $2.13 | +4.9% | $84.06 | $81.75 | -2.7% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $2.01 | $2.04 | +1.5% | $16.40B | +5.0% |
| 2025-09-30 | $2.37 | $2.58 | +8.9% | $17.28B | +3.7% |
| 2025-06-30 | $2.03 | $2.13 | +4.9% | $15.81B | -1.9% |
| 2025-03-31 | $2.14 | $2.22 | +3.7% | $15.53B | -1.6% |
| 2024-12-31 | $1.67 | $1.72 | +3.0% | $15.62B | +6.8% |
| 2024-09-30 | $1.57 | $1.57 | +0.0% | $16.66B | +4.4% |
| 2024-06-30 | $2.15 | $2.28 | +6.0% | $16.11B | +7.2% |
| 2024-03-31 | $1.88 | $2.07 | +10.1% | $15.78B | — |
| 2023-12-31 | $-0.11 | $0.03 | +127.3% | $14.63B | — |
| 2023-09-30 | $1.95 | $2.13 | +9.2% | $15.96B | — |
| 2023-06-30 | $-2.18 | $-2.06 | +5.5% | $15.04B | — |
Analyst EPS and revenue estimates for upcoming years
| Period | EPS estimate | Revenue estimate | Revenue growth | Analysts | Confidence |
|---|---|---|---|---|---|
| 2026 (E) | $5.09 | $67.4B | +3.6% | 17 | high |
| 2027 (E) | $9.81 | $71.0B | +5.4% | 17 | high |
| 2028 (E) | $11.20 | $75.3B | +6.0% | 17 | medium |
| 2029 (E) | $12.50 | $79.9B | +6.2% | 17 | medium |
| 2030 (E) | $13.80 | $84.8B | +6.1% | 17 | medium |
Frequently asked questions
Has Merck & Company Inc beaten earnings estimates?
Merck & Company Inc has beaten Wall Street EPS estimates in 8 of its last 8 quarterly reports, with an average EPS surprise of +4.7% over the last 4 quarters.
How does MRK stock react to earnings?
MRK stock has moved an average of +0.3% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is Merck & Company Inc's revenue growth rate?
Merck & Company Inc reported year-over-year revenue growth of +5.0% in its most recent quarter, with EPS growing +18.6% year-over-year.
What is the expected EPS for MRK in 2026?
Analysts expect Merck & Company Inc to report EPS of $5.09 for fiscal year 2026, on revenue of $67.4B, based on estimates from 17 analysts.